Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Brittinger

Showing results (151-160 of 163) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSFM Engelhard, H Gerhartz, G Brittinger, et al.
Blut|March 1, 1988
German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapyH H Gerhartz, E Thiel, G Brittinger, et al.
Annals of Hematology|December 2, 2000
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemiaM Flasshove, P Meusers, J Schütte, et al.
Blood|April 1, 1997
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factorM Engelhard, G Brittinger, D Huhn, et al.
Der Internist|January 15, 2003
[Chronic lymphatic leukemia. Current therapy concepts]M Hallek, M Bergmann, G Brittinger, et al.
The New England Journal of Medicine|August 16, 1979
Heterogeneity of diffuse "histiocytic" lymphoma according to the Kiel classificationP Meusers, H Bartels, G Brittinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
British Journal of Haematology|September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupM Hallek, B Schmitt, M Wilhelm, et al.
Blut|September 1, 1981
Clinical and prognostic heterogeneity of non-Hodgkin lymphomas of high-grade malignancyU Schmalhorst, H Bartels, I Boll, et al.
Blut|September 1, 1981
Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classificationG Brittinger, U Schmalhorst, H Bartels, et al.
Pageof 17

Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSFM Engelhard, H Gerhartz, G Brittinger, et al.
Blut|March 1, 1988
German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapyH H Gerhartz, E Thiel, G Brittinger, et al.
Annals of Hematology|December 2, 2000
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemiaM Flasshove, P Meusers, J Schütte, et al.
Blood|April 1, 1997
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factorM Engelhard, G Brittinger, D Huhn, et al.
Der Internist|January 15, 2003
[Chronic lymphatic leukemia. Current therapy concepts]M Hallek, M Bergmann, G Brittinger, et al.
The New England Journal of Medicine|August 16, 1979
Heterogeneity of diffuse "histiocytic" lymphoma according to the Kiel classificationP Meusers, H Bartels, G Brittinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
British Journal of Haematology|September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupM Hallek, B Schmitt, M Wilhelm, et al.
Blut|September 1, 1981
Clinical and prognostic heterogeneity of non-Hodgkin lymphomas of high-grade malignancyU Schmalhorst, H Bartels, I Boll, et al.
Blut|September 1, 1981
Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classificationG Brittinger, U Schmalhorst, H Bartels, et al.
Pageof 17